Search | Clinical Trials Finder

Conditions: Severe Hemophilia A
Interventions: Human-cl rhFVIII; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hemophilia A
Interventions: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 19
States / cities: Mountain View, California • Oakland, California • Palo Alto, California + 5 more

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 11 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Las Vegas, Nevada + 2 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, factor IX, factor VIII; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 5 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more

Conditions: Hemophilia A
Interventions: ReFacto; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 6 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more

Conditions: Hemophilia B
Interventions: rFIXFc, FIX; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 4 more

Conditions: Hemophilia A
Interventions: valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Sacramento, California • St Louis, Missouri • Columbus, Ohio

Conditions: Severe Hemophilia A
Interventions: Factor VIII (rFVIIIFc), Advate®; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more

Conditions: Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Interventions: Emicizumab; Drug
Lead sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois; Other
Eligibility: 0 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 12
States / cities: Orange, California • Redwood City, California • Coral Gables, Florida + 9 more

Conditions: Hemophilia B
Interventions: verbrinacogene setparvovec; Genetic
Lead sponsor: Spur Therapeutics; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan

Conditions: Hemophilia A, Hemophilia B, Vitamin D Deficiency
Interventions: Vitamin D and calcium; Dietary Supplement
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 2 Years to 21 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hemophilia A
Interventions: DDAVP Inhalant Product, Exercise Intervention; Drug · Behavioral
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 13 Years to 21 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Indianapolis, Indiana • Akron, Ohio • Columbus, Ohio + 1 more

Conditions: Hemophilia B
Interventions: Not listed
Lead sponsor: Bloodworks; Other
Eligibility: 16 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • New Orleans, Louisiana + 2 more

Conditions: Blood Coagulation Disorders, Hemophilia A
Interventions: Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Orange, California • Sacramento, California • Tampa, Florida + 4 more

Conditions: Hemophilia A, Hemophilia B, Hemarthroses
Interventions: ultrasound; Other
Lead sponsor: Northwell Health; Other
Eligibility: 6 Months to 18 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Hemophilia A
Interventions: SIG-001; Combination Product
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington

Conditions: Factor VIII Deficiency, Congenital
Interventions: Emicizumab; Drug
Lead sponsor: Indiana Hemophilia &Thrombosis Center, Inc.; Other
Eligibility: 5 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hemophilia A
Interventions: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 13
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 10 more

Conditions: Haemophilia A and B With and Without Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 19
States / cities: San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more

Conditions: HIV Infections, Hepatitis C, Hemophilia
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 0 Years to 6 Years · Male only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 34
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 28 more

Conditions: Bone Mineral Density, Hemophilia A, Hemophilia B
Interventions: DXA scan + MRI; Other
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 25 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 0 Years to 6 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more

Conditions: Hemophilia a, Hemophilia B
Interventions: No Intervention; Other
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Greenville, South Carolina

Search by objective public record fields.

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia

Exercise Versus DDAVP in Patients With Mild Hemophilia A

Joint Health Study

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Ultrasonography in Hemophilic Joint Disease and Serum Markers

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Hemlibra in Mild Hemophilia A

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Treatment of Hepatitis C in Hemophilic Patients With HIV

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

Osteoporosis and MRI Study in Hemophilia

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)